Skip to main content

Table 3 Baseline characteristics and association with survival outcomes

From: Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis

Characteristics N % Median PFS (months) HR (95% CI), p value Median OS (months) HR (95% CI), p value
Overall cohort 40 100 15.6   44.6  
Sex       
• Male 24 60.0 14.3 0.473 (0.205–1.092) 43.7 0.591 (0.267–1.308)
• Female 16 40.0 45.3 p = 0.080 51.3 p = 0.194
Age       
• < 60 20 50.0% 15.4 0.691 (0.317–1.509) 43.1 0.569 (0.264–1.223)
• > 60 20 50.0% 16.0 p = 0.354 63.1 p = 0.149
T stage       
• T3 16 40.0% 14.4 0.975 (0.413–2.299) 51.3 1.363 (0.581–3.194)
• T4 18 45.0% 25.5 p = 0.954 44.6 p = 0.477
N stage       
• N1 16 40.0% 13.3 1.108 (0.564–2.175) 43.7 0.978 (0.516–1.852)
• N2 17 42.5% 16.0 p = 0.767 61.7 p = 0.945
Serum CEA level at diagnosis       
• Normal 19 47.5% 48.7 2.879 (1.269–6.534) 74.2 2.355 (1.081–5.133)
• Raised 21 52.5% 12.1 p = 0.011 41.4 p = 0.031
Metastatic sites       
• Single 22 55.0% 16.1 1.090 (0.504–2.361) 44.2 0.869 (0.406–1.859)
• Multiple 18 45.0% 14.4 p = 0.826 51.4 p = 0.717